The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Improving the specificity of prostate cancer screening for early detection of lethal disease.
Hans Lilja
Stock Ownership - Arctic Partners; OPKO Diagnostics
Research Funding - NIH
Other Remuneration - Named on a patent application for a statistical method to detect prostate cancer.; Patents for free PSA, hK2, and intact PSA assays
Andrew J. Vickers
Research Funding - NIH
Other Remuneration - Named on a patent application for a statistical method to detect prostate cancer.
Daniel Sjoberg
Consultant or Advisory Role - OPKO Diagnostics
Robert Johansson
No relevant relationships to disclose
Torvald Granfors
No relevant relationships to disclose
Mattias Johansson
No relevant relationships to disclose
Kim Pettersson
Stock Ownership - Arctic Partners
Other Remuneration - Patent for intact PSA assay
Peter T. Scardino
Consultant or Advisory Role - OPKO Diagnostics
Stock Ownership - OPKO Diagnostics
Research Funding - NCI
Göran Hallmans
No relevant relationships to disclose
Pär Stattin
No relevant relationships to disclose